Published in Cancer Weekly, December 24th, 2002
Revenue for the 9 months ending September 30, 2002, was $8,446,000, compared with revenue of $8,195,000 for the same period last year. Revenue for the 2002 third quarter was $907,000, compared with revenue of $2,843,000 for the same period last year.
"There was a large differential in Nipent sales, when comparing the 2002 third quarter to the 2001 third quarter and the 2002 second quarter," said Dr. Joseph Rubinfeld, chairman and chief executive officer of SuperGen. "This was attributable to a unique buying pattern that resulted from distribution...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.